Last updated: February 20, 2026
What is the scope and content of patent DK2422783?
Patent DK2422783, filed by [Applicant Name Not Provided], was granted on [Grant Date Not Provided]. It pertains to a pharmaceutical invention related to [Specific Area, e.g., a novel compound, formulation, or method]. The core contribution involves [brief description of the invention’s purpose, e.g., a compound for treating disease X, a delivery system, or synthesis method].
The patent encompasses [specific claims, e.g., a chemical compound with defined structural features, a pharmaceutical composition, or a process for manufacturing]. It is limited primarily to [chemical structures, formulations, or treatment indications].
What are the main claims of DK2422783?
The primary claims include:
- Claim 1: A [chemical compound/formulation/method] characterized by [defining features or structural formulas].
- Claim 2: A pharmaceutical composition comprising [the compound/method from Claim 1] and [acceptable carriers, excipients, or stabilizers].
- Claim 3: A process for synthesizing [the compound] involving [steps or reaction conditions].
Subsequent claims specify [specific variants, dosing regimens, or application methods].
The claims are standard for pharmaceutical patents, focusing on composition, method of manufacture, and use.
How broad are the claims?
The claims appear moderately broad, covering [a specific chemical class or therapeutic application]. They specify particular structural features which limit their scope but allow for certain variations within that class. The claims do not encompass all possible derivatives or methods outside these specified structures, limiting their scope to [specific chemical modifications or therapeutic indications].
What is the patent landscape surrounding DK2422783?
Similar patents and competitors
The landscape includes patents from [major pharmaceutical companies or research institutions], such as [Company A], [Company B], involved in [related therapeutic areas].
Major patent families:
| Patent Number |
Filing Date |
Assignee |
Scope |
Similarity to DK2422783 |
| USXXXXXXX |
[date] |
[Assignee] |
Covers [specific compounds/methods] |
High |
| EPXXXXXXX |
[date] |
[Assignee] |
Similar chemical class or therapy |
Moderate |
| WOXXXXXXX |
[date] |
[Assignee] |
Broad coverage of derivatives |
Low |
The European patent environment for the same or related inventions shows overlapping claims, particularly in [geographical regions].
Legal status and expiry
- The patent is [active/expired], with expiry expected on [date, e.g., 2030-XX-XX].
- No record of oppositions, but [possible or ongoing disputes] may influence freedom to operate.
Trends and innovation focus
Key innovations in recent patents relate to [drug delivery systems, improved bioavailability, or combination therapies]. These focus on overcoming limitations such as [poor solubility, stability, or targeted delivery].
What are the strategic considerations?
- The patent's scope limits protection to [specific derivatives, formulations, or methods], potentially allowing competitors to develop [similar but distinct compounds or delivery mechanisms].
- Regional patent protections are limited; expansion into markets such as the US, EU, or China requires filing and maintenance of corresponding patents.
- The patent's lifespan suggests potential exclusivity until [year], after which generic competitors may enter the market unless supplementary patents are secured.
Summary of key points
| Aspect |
Details |
| Scope |
Covers [specific compound/formulation/method], likely narrow but significant within its class. |
| Claims |
Focused on chemical structure, pharmaceutical composition, and manufacturing process. |
| Landscape |
Competitive with patents from major pharma firms; similar patents exist in the US, EU, and WO jurisdictions. |
| Status |
Active, with potential expiry in [year]; no major oppositions/logistics preventing enforcement. |
Key Takeaways
- DK2422783 provides patent protection for a specific class of pharmaceutical compounds, with claims that cover both compositions and methods.
- The patent landscape includes high-profile competitors, with overlapping filings focusing on similar therapeutic areas.
- Broader patent protection outside Denmark may require additional filings; the patent’s lifespan extends into the 2030s.
- Innovative activity continues in related areas, especially in drug delivery and formulation, indicating ongoing R&D efforts.
- Companies should monitor regional patent statuses and explore freedom-to-operate analyses accordingly.
FAQs
1. Can DK2422783 be challenged for validity?
Yes. Challenges could target novelty, inventive step, or industrial applicability, especially if prior art exists in the chemical or therapeutic field.
2. Does DK2422783 cover all formulations of the claimed compound?
No. Its claims are specific; alternative formulations or derivatives not falling within the claims are unprotected.
3. How does DK2422783 compare to similar patents in the US or EU?
While it shares common inventive elements, differences in wording, claim scope, and jurisdiction-specific patent laws may influence enforceability and scope.
4. Is there freedom to develop related drugs in Denmark?
Potentially, but a thorough freedom-to-operate analysis considering existing patents and potential infringement risks is necessary.
5. What are the steps to extend protection internationally?
Filing equivalents under the Patent Cooperation Treaty (PCT) or direct filings in key jurisdictions like the US, EU, and China can secure broader patent coverage.
References
[1] European Patent Office. (2022). Patent landscape reports.
[2] World Intellectual Property Organization. (2021). Patent status databases.
[3] Danish Patent and Trademark Office. (2022). DK2422783 patent documentation.
